Amphista Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Amphista Therapeutics's estimated annual revenue is currently $14.4M per year.
- Amphista Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Amphista Therapeutics has 93 Employees.
- Amphista Therapeutics grew their employee count by 12% last year.
Amphista Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Discovery Technology | Reveal Email/Phone |
3 | VP Drug Discovery | Reveal Email/Phone |
4 | VP Intellectual Property | Reveal Email/Phone |
5 | Chief Technology Officer | Reveal Email/Phone |
6 | Associate Director Medicinal Chemistry | Reveal Email/Phone |
7 | Director Bioinformatics | Reveal Email/Phone |
8 | Director Oncology | Reveal Email/Phone |
9 | Associate Director Medicinal Chemistry | Reveal Email/Phone |
10 | Chief Development Officer | Reveal Email/Phone |
Amphista Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Amphista Therapeutics?
At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches. Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cell's degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.
keywords:N/A
N/A
Total Funding
93
Number of Employees
$14.4M
Revenue (est)
12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Amphista Therapeutics News
AbbVie; Accelero Biostructures; Amgen; Amphista Therapeutics; AnHorn Medicines; Arvinas; Ascentage Pharma; Aurigene Discovery; AUTOTAC Bio...